Antiviral therapies for chronic hepatitis C virus infection with cirrhosis

Table 1 Sustained virological response rates for cirrhotic patients who were treated with direct-acting antiviral agents against hepatitis C virus including peginterferon and ribavirin

Ref. (name of trial)	Regimen; genotype; No. of patients (n)	Tx history	SVR rates	SVR rates for P + R
			Cirrhosis vs Non-cirrhosis
Jacobson et al[10] (ADVANCE)	TVR + P + R; G1; n = 363: P + R; n = 361	-	62% vs 78%1	33% vs 47%
Sherman et al[11] (ILLUMINATE)	TVR + P + R; G1; n = 540	-	63% vs 75%1
Zeuzem et al[12] (REALIZE)	TVR + P + R; G1; n = 530: P + R; n = 132	+	Relapse; 84%-85% vs 83%-90%1	12% vs 38%
			PR; 40%-44% vs 70%-75%	10% vs 18%
			Null; 22%-28% vs 31%-50%	5% vs 6%
Poordad et al[13] (SPRINT-2)	BOC + P + R; G1; n = 734: P + R; n = 363	-	41%-52% vs 67%1	38% vs 38%
Bacon et al[14] (RESPOND-2)	BOC + P + R; G1; n = 299: P + R; n = 76	+; relapse or PR	35%-77% vs 64%-66%	0% vs 24%
Jacobson et al[17]	SMV + P + R; G1; n = 521: P + R; n = 264	-	60% vs 84%23	34% vs 55%
Manns et al[18] (QUEST1/2)
Forns et al[19] (PROMISE)	SMV + P + R; G1; n = 260: P + R; n = 133	+; relapse	74% vs 82%23	26% vs 41%
Zeuzem et al[20] (ASPIRE)	SMV + P + R; G1; n = 199: P + R; n = 66	+	Relapse; 73% vs 95%	0% vs 56%2
			PR; 82% vs 79%	0% vs 8%
			Null; 31% vs 66%	0% vs 23%
Lawitz et al[25] (NEUTRINO)	SOF + P + R; G1, 4-6; n = 327	-	80% vs 92%3

¹Comparison between cirrhosis/bridging fibrosis vs others, or between F3, 4 vs F0-2 (METAVIR score);

²Comparison between F4 vs F0-2 (METAVIR score);

³Data for SVR12. BOC: Boceprevir; G: Genotype; P: Peginterferon; PR: Partial response; R: Ribavirin; SMV: Simeprevir; SVR: Sustained virological response; TVR: Telaprevir; Tx; Treatment; SOF: Sofosbuvir.